Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bet v 1aF1-Alum + Bet v 1aF2-Alum
- Development stage
- Unknown
- Lead developer
- Biomay
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Bet v 1aF1-Alum + Bet v 1aF2-Alum is a combination vaccine formulation designed for allergen-specific immunotherapy (AIT) targeting birch pollen allergy. The active components are recombinant hypoallergenic fragments of the major birch pollen allergen, Bet v 1 (specifically, fragments F1 and F2), each adsorbed to aluminum hydroxide (alum) as an adjuvant. This approach aims to induce immune tolerance by shifting the immune response away from IgE-mediated hypersensitivity toward a more tolerogenic or Th1-biased profile. Recombinant fragment-based vaccines like these offer improved safety and standardization compared to natural extract-based therapies, reducing the risk of severe allergic reactions while effectively modifying disease progression in patients with birch pollen allergy[1][8]. The mechanism involves induction of blocking IgG antibodies against key IgE epitopes on Bet v 1 and modulation of T cell responses[2][3].
- Other names
- Bet v 1aF1-AlumBet v 1aF2-Alum
02
Targets
Bet v 1
Beyond the preview
Go deeper on Bet v 1aF1-Alum + Bet v 1aF2-Alum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bet v 1aF1-Alum + Bet v 1aF2-Alum.